Global Congenital Heart Diseases Market Size, Status and Forecast 2018-2025

Published On: September 2018 | Report ID: 63955 | Category: Pharmaceuticals and HealthcarePages: 98

This report focuses on the global Congenital Heart Diseases status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Congenital Heart Diseases development in United States, Europe and China.

Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these include: large chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.

The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.

In 2017, the global Congenital Heart Diseases market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

The key players covered in this study

Pfizer

Abbott Laboratories

Eli Lilly

Ranbaxy Pharmaceutical

...

Market segment by Type, the product can be split into

Hypoplasia

Obstructive

Septal Defects

Market segment by Application, split into

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Others

Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Congenital Heart Diseases status, future forecast, growth opportunity, key market and key players.

To present the Congenital Heart Diseases development in United States, Europe and China.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Congenital Heart Diseases are as follows:

History Year: 2013-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered

1.4 Market Analysis by Type

1.4.1 Global Congenital Heart Diseases Market Size Growth Rate by Type (2013-2025)

1.4.2 Hypoplasia

1.4.3 Obstructive

1.4.4 Septal Defects

1.5 Market by Application

1.5.1 Global Congenital Heart Diseases Market Share by Application (2013-2025)

1.5.2 Hospitals

1.5.3 Ambulatory Surgical Centers

1.5.4 Diagnostic Centers

1.5.5 Others

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Congenital Heart Diseases Market Size

2.2 Congenital Heart Diseases Growth Trends by Regions

2.2.1 Congenital Heart Diseases Market Size by Regions (2013-2025)

2.2.2 Congenital Heart Diseases Market Share by Regions (2013-2018)

2.3 Industry Trends

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Opportunities

3 Market Share by Key Players

3.1 Congenital Heart Diseases Market Size by Manufacturers

3.1.1 Global Congenital Heart Diseases Revenue by Manufacturers (2013-2018)

3.1.2 Global Congenital Heart Diseases Revenue Market Share by Manufacturers (2013-2018)

3.1.3 Global Congenital Heart Diseases Market Concentration Ratio (CR5 and HHI)

3.2 Congenital Heart Diseases Key Players Head office and Area Served

3.3 Key Players Congenital Heart Diseases Product/Solution/Service

3.4 Date of Enter into Congenital Heart Diseases Market

3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

4.1 Global Congenital Heart Diseases Market Size by Type (2013-2018)

4.2 Global Congenital Heart Diseases Market Size by Application (2013-2018)

5 United States

5.1 United States Congenital Heart Diseases Market Size (2013-2018)

5.2 Congenital Heart Diseases Key Players in United States

5.3 United States Congenital Heart Diseases Market Size by Type

5.4 United States Congenital Heart Diseases Market Size by Application

6 Europe

6.1 Europe Congenital Heart Diseases Market Size (2013-2018)

6.2 Congenital Heart Diseases Key Players in Europe

6.3 Europe Congenital Heart Diseases Market Size by Type

6.4 Europe Congenital Heart Diseases Market Size by Application

7 China

7.1 China Congenital Heart Diseases Market Size (2013-2018)

7.2 Congenital Heart Diseases Key Players in China

7.3 China Congenital Heart Diseases Market Size by Type

7.4 China Congenital Heart Diseases Market Size by Application

8 Japan

8.1 Japan Congenital Heart Diseases Market Size (2013-2018)

8.2 Congenital Heart Diseases Key Players in Japan

8.3 Japan Congenital Heart Diseases Market Size by Type

8.4 Japan Congenital Heart Diseases Market Size by Application

9 Southeast Asia

9.1 Southeast Asia Congenital Heart Diseases Market Size (2013-2018)

9.2 Congenital Heart Diseases Key Players in Southeast Asia

9.3 Southeast Asia Congenital Heart Diseases Market Size by Type

9.4 Southeast Asia Congenital Heart Diseases Market Size by Application

10 India

10.1 India Congenital Heart Diseases Market Size (2013-2018)

10.2 Congenital Heart Diseases Key Players in India

10.3 India Congenital Heart Diseases Market Size by Type

10.4 India Congenital Heart Diseases Market Size by Application

11 Central & South America

11.1 Central & South America Congenital Heart Diseases Market Size (2013-2018)

11.2 Congenital Heart Diseases Key Players in Central & South America

11.3 Central & South America Congenital Heart Diseases Market Size by Type

11.4 Central & South America Congenital Heart Diseases Market Size by Application

12 International Players Profiles

12.1 Pfizer

12.1.1 Pfizer Company Details

12.1.2 Company Description and Business Overview

12.1.3 Congenital Heart Diseases Introduction

12.1.4 Pfizer Revenue in Congenital Heart Diseases Business (2013-2018)

12.1.5 Pfizer Recent Development

12.2 Abbott Laboratories

12.2.1 Abbott Laboratories Company Details

12.2.2 Company Description and Business Overview

12.2.3 Congenital Heart Diseases Introduction

12.2.4 Abbott Laboratories Revenue in Congenital Heart Diseases Business (2013-2018)

12.2.5 Abbott Laboratories Recent Development

12.3 Eli Lilly

12.3.1 Eli Lilly Company Details

12.3.2 Company Description and Business Overview

12.3.3 Congenital Heart Diseases Introduction

12.3.4 Eli Lilly Revenue in Congenital Heart Diseases Business (2013-2018)

12.3.5 Eli Lilly Recent Development

12.4 Ranbaxy Pharmaceutical

12.4.1 Ranbaxy Pharmaceutical Company Details

12.4.2 Company Description and Business Overview

12.4.3 Congenital Heart Diseases Introduction

12.4.4 Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2013-2018)

12.4.5 Ranbaxy Pharmaceutical Recent Development

13 Market Forecast 2018-2025

13.1 Market Size Forecast by Regions

13.2 United States

13.3 Europe

13.4 China

13.5 Japan

13.6 Southeast Asia

13.7 India

13.8 Central & South America

13.9 Market Size Forecast by Product (2018-2025)

13.10 Market Size Forecast by Application (2018-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Disclaimer

15.3 Author Details

Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
Choose License Type



Why Choose Us

  24/7 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Email: sales@marketresearchplace.com

  Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

  Information security

Your personal and confidential information is safe and secure.